ScinoPharm Taiwan, Ltd. (TPE:1789)
Taiwan · Delayed Price · Currency is TWD 18.90
+0.25 (1.34%)
Aug 7, 2026, 1:30 PM CST
ScinoPharm Taiwan Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,068 | 3,163 | 3,406 | 3,186 | 3,264 | 2,762 | |
Revenue Growth | -3.97% | -7.13% | 6.91% | -2.39% | 18.16% | -10.40% |
Cost of Revenue | 2,163 | 2,067 | 2,106 | 1,970 | 2,013 | 1,482 |
Gross Profit | 905.07 | 1,096 | 1,300 | 1,216 | 1,251 | 1,280 |
Selling, General & Admin | 468.79 | 490.3 | 518.14 | 543.83 | 573.88 | 685.79 |
Research & Development | 488.56 | 497.28 | 459.36 | 357.74 | 271.26 | 305.95 |
Operating Expenses | 973.58 | 987.53 | 979.17 | 901.5 | 845.28 | 991.87 |
Operating Income | -68.51 | 108.91 | 321.04 | 314.49 | 405.5 | 288.62 |
Interest Expense | -11.5 | -9.87 | -8.08 | -9.15 | -7.91 | -6.55 |
Interest & Investment Income | 51.4 | 53.38 | 61.52 | 53.63 | 22.12 | 19.38 |
Currency Exchange Gain (Loss) | -30.01 | -30.01 | 19.23 | -16.98 | 41.27 | -7.91 |
Other Non Operating Income (Expenses) | 65.52 | 22.91 | 19.57 | 7.27 | -22.88 | 7.63 |
EBT Excluding Unusual Items | 6.9 | 145.31 | 413.27 | 349.26 | 438.09 | 301.17 |
Gain (Loss) on Sale of Assets | -0.19 | -0.19 | -4.64 | -0.42 | -0.76 | -0.27 |
Asset Writedown | 2.25 | 2.25 | -1.12 | 0 | 0.63 | 1.38 |
Legal Settlements | - | - | 5.5 | - | - | - |
Pretax Income | 8.96 | 147.38 | 413.02 | 348.84 | 437.96 | 302.29 |
Income Tax Expense | -28.77 | 10.42 | 73.67 | 61.78 | 84.74 | 58.82 |
Net Income | 37.73 | 136.95 | 339.35 | 287.06 | 353.22 | 243.47 |
Net Income to Common | 37.73 | 136.95 | 339.35 | 287.06 | 353.22 | 243.47 |
Net Income Growth | -81.57% | -59.64% | 18.22% | -18.73% | 45.07% | -13.68% |
Shares Outstanding (Basic) | 865 | 791 | 791 | 791 | 791 | 791 |
Shares Outstanding (Diluted) | 866 | 792 | 793 | 792 | 793 | 792 |
Shares Change | 9.21% | -0.12% | 0.07% | -0.04% | 0.05% | 0.01% |
EPS (Basic) | 0.04 | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 |
EPS (Diluted) | 0.04 | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 |
EPS Growth | -84.20% | -60.39% | 19.21% | -19.41% | 45.07% | -13.68% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 577.04 | 304.62 | 470.74 | -37.3 | 530.51 | 195.4 |
Free Cash Flow Per Share | 0.67 | 0.39 | 0.59 | -0.05 | 0.67 | 0.25 |
Dividend Per Share | 0.290 | 0.290 | 0.350 | 0.300 | 0.360 | 0.480 |
Dividend Growth | -17.14% | -17.14% | 16.67% | -16.67% | -25.00% | -4.00% |
Gross Margin | 29.50% | 34.66% | 38.17% | 38.17% | 38.32% | 46.36% |
Operating Margin | -2.23% | 3.44% | 9.43% | 9.87% | 12.42% | 10.45% |
Profit Margin | 1.23% | 4.33% | 9.96% | 9.01% | 10.82% | 8.81% |
Free Cash Flow Margin | 18.81% | 9.63% | 13.82% | -1.17% | 16.25% | 7.07% |
EBITDA | 430.48 | 605.01 | 792.08 | 759.82 | 829.1 | 655.41 |
EBITDA Margin | 14.03% | 19.13% | 23.25% | 23.85% | 25.40% | 23.73% |
D&A For EBITDA | 498.99 | 496.11 | 471.04 | 445.33 | 423.61 | 366.79 |
EBIT | -68.51 | 108.91 | 321.04 | 314.49 | 405.5 | 288.62 |
EBIT Margin | -2.23% | 3.44% | 9.43% | 9.87% | 12.42% | 10.45% |
Effective Tax Rate | - | 7.07% | 17.84% | 17.71% | 19.35% | 19.46% |